Loading clinical trials...
Loading clinical trials...
ESKPSY: Esketamine in Real-World Settings: Clinical Outcomes, Predictors of Response, Life Functioning and Biological Pathways
This observational study investigates the use of Esketamine Intranasal Spray in patients with Treatment-Resistant Depression in Real-World Settings. The study aims to evaluate the clinical outcomes, including efficacy and safety, of esketamine treatment. It also explores predictors of treatment response, focusing on biological pathways such as genetics, neuroimaging, and psychophysical measures. Additionally, the study examines how esketamine impacts patients' life functioning, including social and occupational aspects. The goal is to better understand who benefits most from esketamine and how it affects daily life, to improve personalized care for patients with difficult-to-treat depression.
Age
18 - 74 years
Sex
ALL
Healthy Volunteers
No
Ospedale Policlinico San Martino
Genova, Ge, Italy
Csm Dds 8
Genova, Ge, Italy
Università di Chieti
Chieti, Italy
ASST Fatebenefratelli Sacco
Milan, Italy
Start Date
November 1, 2022
Primary Completion Date
July 1, 2026
Completion Date
August 1, 2030
Last Updated
September 24, 2025
100
ESTIMATED participants
Esketamine (Intranasal Spray)
DRUG
Lead Sponsor
Riccardo Guglielmo
NCT07444697
NCT05240352
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05849038